IceCure regains Nasdaq minimum bid compliance

IceCure Medical Ltd. reported that it has regained compliance with Nasdaq’s minimum bid price requirement.

Rhea-AI Filing Summary

IceCure Medical Ltd. reported that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq notified the company on June 18, 2026, after the closing bid price of IceCure’s ordinary shares was at least $1.00 per share for 10 consecutive business days from June 4 to June 17, 2026. With this, Nasdaq now considers the prior bid price deficiency matter closed, confirming the company’s continued listing under Nasdaq Listing Rule 5550(a)(2).

Positive

• IceCure Medical regained compliance with Nasdaq Listing Rule 5550(a)(2), confirming its shares met the $1.00 per share minimum bid price for 10 consecutive business days and closing the prior bid price deficiency matter.

Negative

• None.

Insights

Equity markets analyst

IceCure removes immediate Nasdaq delisting risk by regaining minimum bid compliance.

IceCure Medical received confirmation from Nasdaq that it again meets the minimum bid price requirement in Listing Rule 5550(a)(2), which sets a $1.00 per share threshold. This followed 10 consecutive business days with a closing bid at or above that level.

This development closes the earlier bid price deficiency matter and supports the company’s continued listing on the Nasdaq Capital Market. Maintaining listing status helps keep access to U.S. capital markets and broader investor visibility, though future trading levels will still drive ongoing compliance.

Key Figures

Minimum bid price threshold: $1.00 per share Compliance trading period: 10 consecutive business days Nasdaq notice date: June 18, 2026

3 metrics

Minimum bid price threshold $1.00 per share Nasdaq Listing Rule 5550(a)(2) requirement

Compliance trading period 10 consecutive business days Closing bid at or above $1.00 from June 4–17, 2026

Nasdaq notice date June 18, 2026 Date Nasdaq informed IceCure it had regained compliance

Key Terms

Nasdaq Listing Rule 5550(a)(2), minimum bid price requirement, Report of Foreign Private Issuer, cryoablation, +1 more

5 terms

Nasdaq Listing Rule 5550(a)(2) regulatory

"the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"

minimum bid price requirement regulatory

"regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2)"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

Report of Foreign Private Issuer regulatory

"Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

cryoablation medical

"developer of minimally-invasive cryoablation technology that destroys tumors by freezing"

A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.

Form 6-K regulatory

"this Report of Foreign Private Issuer on Form 6-K"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

FAQ

What did IceCure Medical (ICCM) announce in its June 2026 Form 6-K?

IceCure Medical announced that Nasdaq confirmed the company has regained compliance with its minimum bid price requirement. This followed 10 consecutive business days where IceCure’s closing bid price met or exceeded $1.00 per share, closing the prior deficiency matter.

How did IceCure Medical regain compliance with Nasdaq’s minimum bid price rule?

IceCure Medical regained compliance after its ordinary shares closed at $1.00 per share or higher for 10 consecutive business days. Nasdaq reviewed this trading history from June 4 to June 17, 2026, and then issued a written notice of compliance on June 18, 2026.

Which Nasdaq rule now considers IceCure Medical back in compliance?

IceCure Medical is back in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq determined compliance after the company’s shares met this threshold for 10 consecutive business days in June 2026.

What does closing the bid price deficiency mean for IceCure Medical shareholders?

Closing the bid price deficiency means Nasdaq no longer views IceCure Medical as out of compliance with its minimum bid rule. This supports the company’s continued Nasdaq listing, which can help maintain trading liquidity and access to U.S. public equity investors.

When did Nasdaq notify IceCure Medical about regaining bid price compliance?

Nasdaq notified IceCure Medical on June 18, 2026, that it had regained compliance with the minimum bid price requirement. The decision followed a review of trading from June 4 through June 17, during which the closing bid price met the $1.00 per share threshold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 08:45 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the Month of: June 2026 (Report No. 3)

Commission File Number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

On June 25, 2026, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement,” a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.

This Report on Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 1

EXHIBIT INDEX

Exhibit No.
99.1		Press Release issued by IceCure Medical Ltd., dated June 25, 2026, titled “IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement.”

 2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: June 25, 2026	By:	/s/ Eyal Shamir
		Eyal Shamir
		Chief Executive Officer

 3

Exhibit 99.1 

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

CAESAREA, Israel, June 25, 2026 – IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s ordinary shares was $1.00 per share or greater for the 10 consecutive business days from June 4 to June 17, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the bid price deficiency matter now closed.

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

IR Contact:

Email: investors@icecure-medical.com

Meir Peleg, CFO

Phone: +1-888-902-5716

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE ISSUED BY ICECURE MEDICAL LTD., DATED JUNE 25, 2026, TITLED "ICECU 4.0 KB